Swedish Orphan Biovitrum

Sobi Global

OUR SCIENCE | R&D Innovative medicines in the pipeline Only 5% of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE Financial reports Sobi intends to publish its Q3 2026 report on 27 October 2026.InvitationAide memoire Financial reports MEDIA | PRESS RELEASES Press releases 19 October, 2026 10:15 Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026 16 October, 2026 12:45 Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) Learn more